Anna F. Farago, MD, PhD
Advertisement
Articles by Anna F. Farago, MD, PhD
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.
Advertisement
Latest Updated Articles
Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLCPublished: June 11th 2019 | Updated:
Dr. Anna F. Farago New Cytotoxic Strategies for Relapsed Small-Cell Lung CancerPublished: June 12th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers
2
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
3
Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma
4
Debate Round 3: Timing of Treatment Initiation in LR-MDS (Earlier vs Delayed)
5
